BerGenBio $BGBIO upgraded target price to 86 NOK from ArcticSec
Quote:
"Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly.
Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86.
Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely."
Source:
https://www.research-tree.com/companies/norway/biotechnology/bergenbio-asa/research/arctic-securities/unique-covid-19-possibility/61_6f4403cf-8701-4c9d-bd71-7ddcf7d508a0
"Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly.
Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86.
Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely."
Source:
https://www.research-tree.com/companies/norway/biotechnology/bergenbio-asa/research/arctic-securities/unique-covid-19-possibility/61_6f4403cf-8701-4c9d-bd71-7ddcf7d508a0
Publications connexes
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.